Q1 2023 Non-GAAP Operating Income

Teva Biosimilar Franchise By development stage - as of May 1, 2023 Preclinical Phase 1 Phase 3 Pre-Submission TEV-56285 TEV-54142 TEV-56191 TEV-56261 TEV-56289 TEV-56284* Biosimilar to ProliaⓇ & Xgeva (denosumab) Biosimilar to XolairⓇ (omalizumab) Biosimilar to EyleaⓇ (aflibercept) * Biosimilar to SimponiⓇ (golimumab)* 1. TruximaⓇ and HerzumaⓇ are in collaboration with Celltrion in the U.S. and Canada. |14| Under Regulatory Review Biosimilar to HumiraⓇ (adalimumab)* Biosimilar to StelaraⓇ (ustekinumab)* Commercial Biosimilar Products 1, 2 Herzuma® (trastuzumab-pkrb) For Injection 420 mg/vial • 150 mg/vial Truxima® (rituximab-abbs) Injection for intravenous use 500 mg/50 ml 100 mg/10 ml Pipeline is current as of May 1, 2023 In collaboration with Alvotech for the U.S. market. Teva biosimilar pipeline by development stage, excluding country/regional launches of products submitted or under review in new markets. 2. RanivisioⓇ is in collaboration with BioEq in the UK (marketed as ONGAVIAⓇ), in the EU (to be marketed as RANIVISIOⓇ) and was submitted in Canada Ranivisio 10 mg/ml solution for injection (ranibizumab) teva

View entire presentation